2019 Spring.Includes bibliographical references.The diabetes medication, Dapagliflozin, is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. The mechanism of action is decreasing renal absorption of glucose, leading to glucosuria, and modest weight loss. We hypothesized that SGLT2 inhibition would potentiate the favorable influence of dietary counseling on body composition and physiological adaptations in overweight or obese adults. Fifty sedentary overweight/obese men (n = 12) and women (n = 38) were randomly assigned to 12 weeks of dietary counseling for weight loss, supplemented with daily ingestion of either placebo or Dapagliflozin (up to 10 mg/day); coded as Pill A and Pill B. Dietary counseling consisted of weekly, one-on-one, 30-minute meetings targeting modest calorie restriction. Before and after treatment, body composition, resting metabolic rate (RMR), insulin sensitivity, appetite and satiety were measured. Twelve weeks of dietary counseling decreased (P 0.264). Dietary counseling also decreased lean mass (treatment main effect: P 0.055). Overall, 12-weeks of dietary counseling leads to favorable modification of body mass and fat mass regardless of pill assignment. However, Pill A appears to reduce the dietary counseling mediated loss in lean mass. Except for lean mass, the effects of dietary counseling for weight loss were not influenced by SGLT2 inhibition
